Ephedrine supplements label warning against use for weight loss urged by pediatricians.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE LABEL WARNING AGAINST USE FOR WEIGHT LOSS SUGGESTED by the American Academy of Pediatrics in Aug. 15 comments to FDA. Noting the agency has proposed that ephedrine-containing dietary supplements should not be allowed to carry weight loss claims, AAP recommends additional "inclusion of statements advising that such products are not intended for use as an intervention for weight loss." The group supports "full disclosure labeling of such products and oppose[s] any suggestive claims designed to make these products more appealing to children, particularly adolescents."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning